Development and therapeutic potential of incretin hormone analogues for type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 3, 2005, Pages 134-140

  Green, Brian D ^a   Irwin, Nigel ^b   Gault, Victor A ^b   O'Harte, Finbarr P M ^b   Flatt, Peter R ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b NONE

Author keywords

Diabetes; GIP; GLP 1; Incretin hormones

Indexed keywords

1 [4 METHYL 1 (2 PYRIMIDINYL) 4 PIPERIDYLAMINOACETYL] 2 PYRROLIDINECARBONITRILE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACARBOSE; ALBUGON; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BIM 51077; CARBOHYDRATE; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE DERIVATIVE; INCRETIN HORMONE DERIVATIVE; INSULIN; LIRAGLUTIDE; LY 315902; MEGLITINIDE; MIGLITOL; PEPTIDE DERIVATIVE; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZP 10A;

CARBOHYDRATE ABSORPTION; CLINICAL TRIAL; DIET THERAPY; DIZZINESS; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; GLOMERULUS FILTRATION; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET CELL; POSTPRANDIAL STATE; PREVALENCE; PROTEIN DEGRADATION; REVIEW; VOMITING;

EID: 21644433606     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050030401     Document Type: Review

References (44)

1. Unger RH, Eisentraut AM. Entero-insular axis. Arch Int Med 1969;123: 261-6.
2. Knowler WC, Pettitt DJ, Saad MF et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nut 1991;53: 1543S-51S.
3. Ohneda M, Inman LR, Unger RH. Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia 1995;38:173-9.
4. Inzucchi SE. Oral antihperglycaemic therapy for type 2 diabetes. JAMA 2002;287:360-72.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
6. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003;308:207-13.
7. Göke R, Wagner B, Fehmann HC, Goke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 1993;193:97-103.
8. Green BD, Gault VA, O'Harte FPM, Flatt PR. Structurally modified analogues of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as future antidiabetic agents. Curr Pharm Des 2004;10:3651-62.
9. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-58.
10. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
11. Kindmark H, Pigon J, Efendic S. Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab 2001;86:2015-19,
12. Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 2004;53:2359-65.
13. Groop PH, Groop L, Totterman KJ, Fyhrquist F. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol 1986; 112:361-6.
14. Meier JJ, Goetze O, Anstipp J et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004;286:E621-E625.
15. Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801.
16. Barrett AJ, Rawlings ND. Oligopeptidases, and the emergence of the prolyl oligopeptidase family. Biol Chem 1992; 373:353-60.
17. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-35.
18. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FPM. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002;175:525-33.
19. Meier JJ, Nauck MA, Kranz D et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects, Diabetes 2004;53:654-62.
20. Gappa H, Baudys M, Koh JJ, Kim SW, Bae YH. The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets. Tissue Eng 2001; 7:35-44.
21. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 1996;19:843-8.
22. Burcelin R, Rolland E, Dolci W, Germain S, Carrel V, Thorens B. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N Y Acad Sci 1999;875:277-85.
23. O'Harte FPM, Gault VA, Parker JC et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002;45:1281-91.
24. Gault VA, Flatt PR, Bailey CJ et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 2002;367:913-20.
25. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85:9-24.
26. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FPM. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion and in vivo antidiabetic actions following substitution of Ala8/Ala2 for 2-aminobutyric acid. Arch Biochem Biophys 2004; 428: 136-43.
27. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003;10:2471-83.
28. Kapitza C, Trautmann ME, Heise T, Heinemann L, Patterson, B. Daily Administration of LY307161 SR (GLP-1 Analog) Normalizes Blood Glucose in Type 2 Diabetes. Diabetes ADA Meeting San Francisco 2002; 341-OR.
29. Giannoukakis N. CJC-1131. ConjuChem. Curr Opin Investig Drugs 2003;4:1245-9.
30. Mark M. NN-2211. Novo Nordisk. IDrugs 2003;6:251-8.
31. Kreymann B, Williams G, Ghatei, MA, Bloom, SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2:1300-04.
32. Meier JJ, Nauck MA, Siepmann N et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003;52:1579-85.
33. Nauck MA, El-Ouaghlidi A, Gabrys B et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209-17.
34. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52:380-6.
35. Meier JJ, Gallwitz B, Kask B et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004;53:S220-S224.
36. Lindsay JR, Au STB, Kelly CMN, O'Harte FPM, Flatt PR. A novel aminoterminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes 2002;5:1394.
37. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999;42:1324-31.
38. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000;404:239-45.
39. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002;172:355-62.
40. Ahren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75.
41. Mentlein R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin Investig Drugs 2005; 14:57-64.
42. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983;32:433-5.
43. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol 1986;112:224-9.
44. Miyawaki K, Yamada Y, Ban N et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42.